Morgan Stanley
NAMS icon

Morgan Stanley’s NewAmsterdam Pharma NAMS Stock Holding History

Morgan Stanley’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5M Buy
575,825
+20,064
+4% +$661K ﹤0.01% 3122
2026
Q1 		$17.8M Buy
555,761
+22,958
+4% +$748K ﹤0.01% 3064
2025
Q4 		$18.7M Sell
532,803
-964,676
-64% -$35.1M ﹤0.01% 3005
2025
Q3 		$42.6M Buy
1,497,479
+859,772
+135% +$20.6M ﹤0.01% 2152
2025
Q2 		$11.5M Buy
637,707
+200,168
+46% +$3.65M ﹤0.01% 3307
2025
Q1 		$8.96M Buy
437,539
+7,437
+2% +$165K ﹤0.01% 3444
2024
Q4 		$11.1M Buy
430,102
+226,897
+112% +$4.82M ﹤0.01% 3314
2024
Q3 		$3.37M Buy
203,205
+178,513
+723% +$3.09M ﹤0.01% 4265
2024
Q2 		$474K Sell
24,692
-152,896
-86% -$3.07M ﹤0.01% 5315
2024
Q1 		$4.2M Buy
177,588
+149,050
+522% +$3.03M ﹤0.01% 4044
2023
Q4 		$319K Buy
28,538
+26,836
+1,577% +$246K ﹤0.01% 5519
2023
Q3 		$15.7K Buy
1,702
+894
+111% +$9.68K ﹤0.01% 6555
2023
Q2 		$9.61K Buy
808
+305
+61% +$4.05K ﹤0.01% 6826
2023
Q1 		$6.67K Buy
+503
New +$6.35K ﹤0.01% 6994

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Morgan Stanley's NAMS Position: Q2 2026 in Review

Morgan Stanley increased its NewAmsterdam Pharma (NAMS) stake by 3.6% in Q2 2026, buying an estimated $661K and bringing the position to 575,825 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3122.

Morgan Stanley first reported a position in NAMS in Q1 2023 and has held it in 14 quarters since. The position peaked at $42.6M in Q3 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Morgan Stanley held 575,825 shares of NewAmsterdam Pharma worth $19.5M as of Q2 2026.
  • Morgan Stanley bought 20,064 NewAmsterdam Pharma shares in Q2 2026, an estimated $661K.
  • NewAmsterdam Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3122 holding.
  • Morgan Stanley first reported a position in NewAmsterdam Pharma in Q1 2023 and has held it in 14 quarters since.
  • Morgan Stanley's NewAmsterdam Pharma position peaked at $42.6M in Q3 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.